The negotiation was a simple one. Vaccine makers needed an assured market, and the government, assured supply. Until recently, the lowest bidder for a government tender took it all. Not anymore. The supplier who scores the second place also has value. After a year of dialogue in 2016, there’s finally a consensus. The lowest bidder will supply 60% of the products, while the second lowest will meet the remaining need. Provided, the latter matches the lowest price.

Under the revised rules, on 28 March, the ministry of health closed its first bid to buy 14.5 million doses of rotavirus vaccine for Rs 104.13 crore. After giving two orders of 10 million doses each to Bharat Biotech (Bharat) since its Rotavac launch in March 2015, the ministry is pleased that this time it has an option. Pune-based Serum Institute of India (Serum), the world’s largest vaccine manufacturer by the number of doses produced, is competing with the poster boy of the Indian vaccine industry—Hyderabad-based Bharat. The latter has the first-mover advantage and low price on its side but Serum offers an advanced product.

When Bharat launched Rotavac, two years ago, it was a dollar a dose. Also, the cheapest in comparison with what competitors GlaxoSmithKline (GSK) and Merck were selling in India. It was developed with support from the Indian and the US governments and non-government organisations including the Bill and Melinda Gates Foundation (BMGF). It couldn’t have been better timed because a year later, the Modi government included the rotavirus vaccine in the Universal Immunisation Programme (UIP) in four states—Andhra Pradesh, Haryana, Himachal Pradesh and Odisha. Rotavirus diarrhoea kills between 80,000 to 100,000 children every year.

Meanwhile, slowly and steadily, Serum had been developing a different product, more in tune with the global market. For two dollars a dose, Serum’s Rotasiil offers higher stability, a longer shelf life and reduced wastage with its small doses. No less importantly, it has pushed the government to change its ways of buying from the industry as the vaccine demand for the UIP soars.

More vaccine quantities and the number of children being immunised, up from 65% to 90% by 2020, under the new plan, have been like a booster dose for the Indian vaccine makers. The guaranteed minimum of 40% to the second lowest bidder is a turning point. The current UIP budget of Rs 1000 crore for 2017-18 will see nearly twice the number of suppliers for different vaccines, the credit for which goes to two companies—Bharat and Serum.

Doubling of suppliers

The guaranteed minimum of 40% to the second lowest bidder is a turning point. The current UIP budget of Rs 1000 crore for 2017-18 will see nearly twice the number of suppliers for different vaccines, the credit for which goes to two companies—Bharat and Serum

The hare & the tortoise

The story of Rotavac’s development started in 1985.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?

MOST POPULAR

Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750

Subscribe
 

Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500

Subscribe
MOST POPULAR

Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120

Subscribe
 

Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

$ 20

Subscribe

Questions?

What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.